This HTML5 document contains 78 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/AHFS/
n21http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/bindingdb/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/pubchem-substance/
n19http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/iuphar/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/guide-to-pharmacology/
admshttp://www.w3.org/ns/adms#
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB01184/identifier/chebi/
n17http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01184
rdf:type
n5:Drug
n5:description
A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem]
n5:dosage
n22:271B5090-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9663360
n5:group
investigational approved
n5:halfLife
7 hours
n5:indication
For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
owl:sameAs
n19:DB01184 n20:DB01184
dcterms:title
Domperidone
adms:identifier
n4:965 n8:965 n9:DB01184 n10:3151 n11:46508314 n12:PA134711056 n13:D01745 n14:Domperidone n24:31515 n25:3039 n26:50241107
n5:mechanismOfAction
Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting
n5:packager
n21:271B5087-363D-11E5-9242-09173F13E4C5
n5:synonym
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one 5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone Domperidonum Domperidona 1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one 5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one
n5:toxicity
Side effects include galactorrhea, gynecomastia, or menstrual irregularities.
n15:hasAHFSCode
n16:56-92-00 n16:56-32-00
n5:foodInteraction
Take 15 to 30 minutes before meals.
n5:proteinBinding
91%-93%
n5:synthesisReference
Vanderberk, J., Kennis, L.E.J., Van der Aa, M.J.M.C. and Van Heertum, A.H.M.T.; U.S. Patents 4,066,772; January 3,1978; 4.1 10,333; August 29,1978; 4,126,687; November 21, 1978; 4,126,688; November 21,1978; 4,160,836; July 10,1979 and 4,175,129; November 20,1979; all assigned to Janssen Pharmaceutica NV (Belgium).
n5:IUPAC-Name
n7:271B5095-363D-11E5-9242-09173F13E4C5
n5:InChI
n7:271B509B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n7:271B509A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B5097-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n7:271B5098-363D-11E5-9242-09173F13E4C5
n5:SMILES
n7:271B5099-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n7:271B5093-363D-11E5-9242-09173F13E4C5 n7:271B50AB-363D-11E5-9242-09173F13E4C5
n5:logP
n7:271B5091-363D-11E5-9242-09173F13E4C5 n7:271B50AD-363D-11E5-9242-09173F13E4C5 n7:271B5094-363D-11E5-9242-09173F13E4C5
n5:logS
n7:271B5092-363D-11E5-9242-09173F13E4C5
n5:pKa
n7:271B50AE-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n17:A03FA03
n5:H-Bond-Acceptor-Count
n7:271B50A1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n7:271B50A2-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n7:271B509C-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n7:271B509D-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n7:271B509F-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n7:271B509E-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n7:271B50A0-363D-11E5-9242-09173F13E4C5
n5:absorption
Fast
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
57808-66-9
n5:containedIn
n6:271B5089-363D-11E5-9242-09173F13E4C5 n6:271B508F-363D-11E5-9242-09173F13E4C5 n6:271B508B-363D-11E5-9242-09173F13E4C5 n6:271B508D-363D-11E5-9242-09173F13E4C5 n6:271B508E-363D-11E5-9242-09173F13E4C5 n6:271B508A-363D-11E5-9242-09173F13E4C5 n6:271B508C-363D-11E5-9242-09173F13E4C5 n6:271B5088-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n7:271B50A7-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n7:271B50A9-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n7:271B50AA-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n7:271B50AC-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n7:271B50A6-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n7:271B50A5-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n7:271B50A8-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n7:271B5096-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n7:271B50A3-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n7:271B50A4-363D-11E5-9242-09173F13E4C5